Protocol Ledger

NCT05245474 · Phase II · RECRUITING

Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Interventional Phase II clinical trial protocol NCT05245474 sponsored by Beijing Friendship Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-01 Enrollment: 186 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05245474
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)186 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05245474
Protocol FieldVerified Registry Value
NCT IdentifierNCT05245474
Consolidated Lead SponsorBeijing Friendship Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment186 participants (ESTIMATED)
Registered Start Date2022-04-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI